[go: up one dir, main page]

AR052377A2 - Polipeptidos y polinucleotidos de neisseria meningitidis, un huesped unicelular, un metodo para producir una secuencia de adn, un metodo para producir un polipeptido, un metodo para aislar el antigeno, una composicion farmaceutica, uso de una proteina para producir una vacuna destinada para la preve - Google Patents

Polipeptidos y polinucleotidos de neisseria meningitidis, un huesped unicelular, un metodo para producir una secuencia de adn, un metodo para producir un polipeptido, un metodo para aislar el antigeno, una composicion farmaceutica, uso de una proteina para producir una vacuna destinada para la preve

Info

Publication number
AR052377A2
AR052377A2 ARP060100562A ARP060100562A AR052377A2 AR 052377 A2 AR052377 A2 AR 052377A2 AR P060100562 A ARP060100562 A AR P060100562A AR P060100562 A ARP060100562 A AR P060100562A AR 052377 A2 AR052377 A2 AR 052377A2
Authority
AR
Argentina
Prior art keywords
produce
neisseria meningitidis
polypeptides
polypeptide
dna sequence
Prior art date
Application number
ARP060100562A
Other languages
English (en)
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26669758&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052377(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of AR052377A2 publication Critical patent/AR052377A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Polipéptidos y polinucleotidos de Neisseria meningitidis, un huésped unicelular, un método para producir una secuencia de ADN, un método para producir un polipéptido, un método para aislar el antígeno, una composicion farmacéutica, uso de una proteína para producir una vacuna destinada para la prevencion de la infeccion de Neisseria gonorrhoeae, un anticuerpo o fragmento del mismo, un anticuerpo monoclonal o fragmento del mismo, un método para aislar un anticuerpo monoclonal, un método para la deteccion del antígeno Neisseria meningitidis en una muestra biologica y el uso de la proteína de superficie Neisseria meningitidis de 22 kda o un fragmento, análogo, o derivado del mismo para producir un kit para la deteccion o diagnostico de la infeccion de Neisseria meningitidis. Un antígeno aislado o un fragmento del mismo que es inmunologicamente accesible en más de un 50% de las cepas conocidas de Neisseria meningitidis.
ARP060100562A 1995-03-17 2006-02-16 Polipeptidos y polinucleotidos de neisseria meningitidis, un huesped unicelular, un metodo para producir una secuencia de adn, un metodo para producir un polipeptido, un metodo para aislar el antigeno, una composicion farmaceutica, uso de una proteina para producir una vacuna destinada para la preve AR052377A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40636295A 1995-03-17 1995-03-17
US198395P 1995-08-04 1995-08-04

Publications (1)

Publication Number Publication Date
AR052377A2 true AR052377A2 (es) 2007-03-14

Family

ID=26669758

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP960101796A AR002970A1 (es) 1995-03-17 1996-03-18 Composiciones farmacéuticas que comprenden polipéptidos de neisseria, microorganismo modificado y vectores que comprenden polinucleótidos de neisseria.
ARP060100562A AR052377A2 (es) 1995-03-17 2006-02-16 Polipeptidos y polinucleotidos de neisseria meningitidis, un huesped unicelular, un metodo para producir una secuencia de adn, un metodo para producir un polipeptido, un metodo para aislar el antigeno, una composicion farmaceutica, uso de una proteina para producir una vacuna destinada para la preve

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP960101796A AR002970A1 (es) 1995-03-17 1996-03-18 Composiciones farmacéuticas que comprenden polipéptidos de neisseria, microorganismo modificado y vectores que comprenden polinucleótidos de neisseria.

Country Status (24)

Country Link
EP (1) EP2241625A1 (es)
JP (3) JPH11500624A (es)
KR (1) KR100361562B1 (es)
AP (1) AP1027A (es)
AR (2) AR002970A1 (es)
AU (1) AU716225B2 (es)
BR (1) BR9607651B8 (es)
CA (1) CA2215161C (es)
CZ (2) CZ298646B6 (es)
EA (1) EA001789B1 (es)
GE (1) GEP20032977B (es)
HU (1) HUP9702387A3 (es)
IL (1) IL117483A (es)
MX (1) MX9707061A (es)
NO (1) NO326425B1 (es)
NZ (1) NZ303118A (es)
OA (1) OA10742A (es)
PL (1) PL184373B1 (es)
RO (1) RO117924B1 (es)
SI (1) SI9620035A (es)
SK (1) SK287456B6 (es)
TR (1) TR199700971T1 (es)
TW (1) TW520375B (es)
WO (1) WO1996029412A1 (es)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0909323B1 (en) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Helicobacter pylori bacterioferritin
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
WO1999024578A2 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
CN1224708C (zh) * 1998-01-14 2005-10-26 启龙股份公司 脑膜炎奈瑟氏球菌抗原
EP2261350A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
CN1911959A (zh) * 1998-10-09 2007-02-14 希龙公司 奈瑟球菌基因组序列及其用途
CA2359492A1 (en) 1999-01-15 2000-07-20 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigen
ATE386541T1 (de) 1999-02-22 2008-03-15 Health Prot Agency Neisseria impfstoffzusammensetzungen und methoden
US7081244B2 (en) 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
RU2233328C2 (ru) * 1999-04-30 2004-07-27 Чирон Корпорейшн Белок, полученный из neisseria meningitidis, проявляющий свойства антигена, антитело, нуклеиновая кислота (варианты) и содержащая их композиция
NZ530640A (en) 1999-04-30 2006-06-30 Chiron S Conserved neisserial antigens
GB9910168D0 (en) * 1999-04-30 1999-06-30 Chiron Spa Conserved antigens
NZ545647A (en) * 1999-05-19 2008-02-29 Chiron Srl Combination neisserial compositions
AU2013203304B2 (en) * 1999-05-19 2014-10-09 Glaxosmithkline Biologicals S.A. Combination Neisserial compositions
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
PT2275552E (pt) * 1999-10-29 2015-12-07 Glaxosmithkline Biolog Sa Péptidos antigénicos de neisseria
EP1234039A2 (en) 1999-11-29 2002-08-28 Chiron Spa 85kDa NEISSERIAL ANTIGEN
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
BR0107679A (pt) 2000-01-17 2004-07-06 Chiron Spa Vacina de vesìcula de membrana externa (omv) compreendendo proteìnas de membrana externa do grupo sérico b de neisseria meningitidis
AU2001239488B2 (en) 2000-02-28 2006-01-19 Glaxosmithkline Biologicals S.A. Heterologous expression of neisserial proteins
AU2001280883A1 (en) 2000-07-27 2002-02-13 The Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
ATE439372T1 (de) 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic Nukleinsäuren und proteine von gruppen a und b- streptokokken
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2002366592B2 (en) 2001-12-12 2008-01-10 Novartis Vaccines And Diagnostics S.R.L. Immunisation against Chlamydia trachomatis
US7501134B2 (en) 2002-02-20 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
JP4740738B2 (ja) 2002-08-02 2011-08-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0220197D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Refolding method
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
JP4579156B2 (ja) 2002-11-01 2010-11-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原組成物
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
CA2520124A1 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of benzazole compounds for immunopotentiation
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
WO2005032584A2 (en) 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CU23237A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
CA2575548A1 (en) 2004-07-29 2006-07-27 John L. Telford Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
EP2682126B1 (en) 2005-01-27 2016-11-23 Children's Hospital & Research Center at Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
JP2009511636A (ja) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
ES2376492T3 (es) 2006-03-23 2012-03-14 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores.
US20090123499A1 (en) 2006-06-12 2009-05-14 Nathalie Devos Vaccine
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
ES2561483T3 (es) 2007-09-12 2016-02-26 Glaxosmithkline Biologicals Sa Antígenos mutantes de GAS57 y anticuerpos de GAS57
ATE553774T1 (de) 2007-10-19 2012-05-15 Novartis Ag Meningokokkenimpfstoffformulierungen
EP2244695A1 (en) 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
PL2235046T3 (pl) 2007-12-21 2012-12-31 Novartis Ag Zmutowane formy streptolizyny O
BRPI0907843A2 (pt) 2008-02-21 2015-08-04 Novartis Ag Polipeptídeos de fhbp menigocócicos
ES2546213T3 (es) 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
PL2349520T3 (pl) 2008-10-27 2017-08-31 Glaxosmithkline Biologicals Sa Sposób oczyszczania węglowodanów z paciorkowców grupy a
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
WO2010078556A1 (en) 2009-01-05 2010-07-08 Epitogenesis Inc. Adjuvant compositions and methods of use
CA2749367A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
RU2557315C2 (ru) 2009-03-24 2015-07-20 Новартис Аг Адъювантный менингококковый белок, связывающий фактор н
NZ595291A (en) 2009-03-24 2013-08-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
EP2470205A1 (en) 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
JP2013506651A (ja) 2009-09-30 2013-02-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ．ａｕｒｅｕｓ５型および８型莢膜多糖の結合体
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
DK2493498T3 (en) 2009-10-30 2017-05-08 Glaxosmithkline Biologicals Sa Purification of Staphylococcus aureus type 5 and type 8 capsule saccharides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
MX339146B (es) 2009-12-15 2016-05-13 Novartis Ag Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos.
CN102869377A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EA023725B1 (ru) 2010-03-23 2016-07-29 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
EP4036104B1 (en) 2010-03-30 2024-02-21 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
CN103154034B (zh) 2010-04-13 2016-06-08 塞尔德克斯医疗公司 结合人cd27的抗体及其用途
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
PT2608805T (pt) 2010-08-23 2017-09-11 Wyeth Llc Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
EP2723378A4 (en) 2011-06-24 2015-01-28 Epitogenesis Inc PHARMACEUTICAL COMPOSITIONS COMPRISING A COMBINATION OF VECTORS, VITAMINS, TANNINS AND FLAVONOIDS SELECTED AS ANTIGEN-SPECIFIC IMMUNOMODULATORS
WO2013098589A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
JP5957541B2 (ja) 2012-02-02 2016-07-27 ノバルティス アーゲー 髄膜炎菌における増加したタンパク質発現のためのプロモータ
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
JP5925342B2 (ja) 2012-03-09 2016-05-25 ファイザー・インク 髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法
BR112014031386A2 (pt) 2012-06-14 2017-08-01 Pasteur Institut vacinas para meningococos do sorogrupo x
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3110442B1 (en) 2014-02-28 2020-10-14 GlaxoSmithKline Biologicals SA Modified meningococcal fhbp polypeptides
JP6796057B2 (ja) 2014-07-23 2020-12-02 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド Ｈ因子結合タンパク質変異体及びその使用方法
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
MA41842A (fr) 2015-03-31 2018-02-06 Oblique Therapeutics Ab Nouveaux procédés de sélection d'épitope
BE1024634B1 (fr) 2016-04-05 2018-05-14 Gsk Vaccines S.R.L. Compositions immunogenes
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
GB201617002D0 (en) 2016-10-06 2016-11-23 Oblique Therapeutics Ab Multi-protease method
IL303108B2 (en) 2017-01-31 2024-07-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
SG11202010011RA (en) 2018-04-17 2020-11-27 Celldex Therapeutics Inc Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
MX2023011788A (es) 2021-04-09 2023-10-11 Celldex Therapeutics Inc Anticuerpos contra ilt4, anticuerpo biespecifico anti-ilt4/pd-l1 y usos de los mismos.
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273116A3 (en) * 1986-10-09 1990-05-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gonococcal and meningococcal polypeptides, vaccines and diagnostics
AU5093693A (en) * 1992-08-31 1994-03-29 Global Tek, Inc. Monoclonal antibody to cell surface protein of the bacterium neisseria meningitidis

Also Published As

Publication number Publication date
IL117483A (en) 2008-03-20
CZ298052B6 (cs) 2007-06-06
KR100361562B1 (ko) 2004-05-20
CZ291497A3 (cs) 1998-01-14
IL117483A0 (en) 1996-07-23
BR9607651A (pt) 1998-11-17
JP2003189879A (ja) 2003-07-08
BR9607651B8 (pt) 2014-08-05
NO326425B1 (no) 2008-12-01
AP1027A (en) 2001-11-23
JP4271231B2 (ja) 2009-06-03
JP4109939B2 (ja) 2008-07-02
OA10742A (en) 2002-12-10
HUP9702387A3 (en) 1999-09-28
EA001789B1 (ru) 2001-08-27
JPH11500624A (ja) 1999-01-19
SK287456B6 (sk) 2010-10-07
WO1996029412A1 (en) 1996-09-26
EP2241625A1 (en) 2010-10-20
EA199700248A1 (ru) 1998-04-30
KR19980703099A (ko) 1998-10-15
PL184373B1 (pl) 2002-10-31
AP9701118A0 (en) 1997-10-31
HUP9702387A1 (hu) 1998-05-28
CA2215161A1 (en) 1996-09-26
NZ303118A (en) 2000-07-28
CA2215161C (en) 2012-10-30
PL322363A1 (en) 1998-01-19
AR002970A1 (es) 1998-05-27
AU4934396A (en) 1996-10-08
RO117924B1 (ro) 2002-09-30
NO974264L (no) 1997-11-13
AU716225B2 (en) 2000-02-24
NO974264D0 (no) 1997-09-15
GEP20032977B (en) 2003-05-27
CZ298646B6 (cs) 2007-12-05
SI9620035A (sl) 1998-12-31
TW520375B (en) 2003-02-11
HK1014991A1 (zh) 1999-11-19
SK125597A3 (en) 1998-06-03
JP2007159583A (ja) 2007-06-28
TR199700971T1 (xx) 1998-04-21
BR9607651B1 (pt) 2011-02-08
MX9707061A (es) 1998-08-30

Similar Documents

Publication Publication Date Title
AR052377A2 (es) Polipeptidos y polinucleotidos de neisseria meningitidis, un huesped unicelular, un metodo para producir una secuencia de adn, un metodo para producir un polipeptido, un metodo para aislar el antigeno, una composicion farmaceutica, uso de una proteina para producir una vacuna destinada para la preve
Finkelstein et al. Production of highly purified choleragen and choleragenoid
BR9306984A (pt) Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo
ES2120046T3 (es) Procedimiento de preparacion de inmunogenos o reactivos de diagnostico e inmunogenos o reactivos de diagnostico obtenibles por dicho procedimiento.
KR900009095A (ko) 합성 항원, 이의 제조방법 및 용도
NO924780L (no) Ekspresjon av spesifikke immunogener ved bruk av virusantigener
KR900700507A (ko) Htlv-1 감염 검출용 합성 펩티드 항원
ATE128627T1 (de) Immunomodulare mittel und deren verwendung.
NO984244L (no) Vaksinesammensetninger og fremgangsmÕter som er nyttige i Õ indusere immunbeskyttelse mot artritogene peptider som er involvert i patogenese av reumatoid artritt
AR033832A1 (es) Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo
FR2660757B1 (fr) Procede d'identification ou de dosage de proteines et applications.
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
DK0494294T3 (da) Bakterielle stressproteiner
Dardenne et al. Characterization of facteur thymique sérique (FTS) in the thymus. II. Direct demonstration of the presence of FTS in thymosin fraction V
Schleifer et al. The Immunochemistry of Peptidoglycan: Separation and Characterization of Antibodies to the Glycan and to the Peptide Subunit
ATE94880T1 (de) Synthetische peptide, gegen diese gerichtete antikoerper und deren verwendung.
Feinberg A ‘microspot’test for antigens and antibodies
US7169393B2 (en) Antigenic peptide fragments of VapA protein, and uses thereof
AR004567A1 (es) Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi.
EP0879244A4 (en) RECOMBINANT POLYPEPTIDE VACCINE AGAINST MYCOPLASMS.
ATA7285A (de) Verfahren zur herstellung von polydispersen nativen pseudomonas-flagella(h)-antigenen (fag)
ATE366583T1 (de) Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407
DE502004008729D1 (de) Gegen das Prothrombin-Fragment F1+2 gerichtete Antikörper, ihre Herstellung und Verwendung
Krailas et al. Production of monoclonal antibodies against partially purified surface tegument antigens of Fasciola gigantica
Walter et al. Chemical, serologic, and dermal hypersensitivity activities of two fractions of histoplasmin

Legal Events

Date Code Title Description
FB Suspension of granting procedure